CA-NETAPP
7.6.2022 14:02:37 CEST | Business Wire | Press release
NetApp ® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced continued innovations and solutions to provide enterprises with more simplicity, more security and more flexibility for their hybrid multicloud environments.
These new capabilities include improved ransomware protection, hybrid cloud storage in a single subscription, unified management in a single user interface, and close collaboration with VMware to help transition workloads to the cloud.
As enterprises acquire public cloud services to augment their existing on-premises data centers, these combined infrastructures become more disparate, inconsistent and fragmented over time. These multicloud silos are inherently more complex to manage due to dealing with multiple disparate environments.
Today, NetApp is delivering a unified and consistent hybrid multicloud experience, allowing customers to run and manage a single platform that spans from on-premises to the world’s biggest public clouds.
“As organizations today explore the promise of hybrid multicloud environments, they are keen to avoid complexity, security, and cost efficiency challenges,” said Ronen Schwartz, senior vice president, Cloud Volumes Service at NetApp. “With NetApp’s simplified management and consumption experience, organizations can enjoy improved security, manageability, speed of operations, and cost savings - ultimately allowing them to be more responsive to the growing needs of their business by delivering capabilities faster, and keeping data available and protected no matter where it lives.”
Simple, secure, and flexible enhancements to NetApp’s hybrid cloud portfolio include:
Industry-Leading Hybrid Cloud Simplicity Experience –
By delivering everything "as a service," NetApp simplifies and optimizes hybrid cloud environments with new capabilities, including:
- Hybrid cloud Storage-as-a-Service (STaaS) in a single, flexible subscription with Keystone. Organizations can flexibly move workloads to and from the cloud in a single contract.
- In addition to managing and monitoring data storage, protection, governance and tiering across multicloud environments, Cloud Manager can now manage Keystone services, track software licenses, monitor infrastructure health and provide proactive recommendations that optimize costs and data protection with automated actions.
"Organizations today are looking for flexibility both on-premises as well as across cloud providers and are investing in as-a-service consumption models to help achieve this," said Scott Sinclair, practice director at ESG. "NetApp's approach with Keystone is targeted at that need; offering hybrid cloud simplicity and flexibility that allows users to accelerate their IT objectives with management, orchestration, and billing wrapped into a single subscription and experience. Keystone's transferable subscription model also supports future cloud migration planning to any major cloud provider, with enterprise-level storage capability and integrated data protection."
Cyber Resilience for Today’s Hybrid Cloud –
The rise of ransomware over the past few years is a growing problem for enterprises. IDC’s 2021 Ransomware Study: Where You Are Matters! 1 found that more than one third of organizations worldwide have experienced a ransomware attack or breach that blocked access to systems or data in the 12 months prior.
With NetApp’s new, powerful, built-in cyber resilience capabilities that include anti-ransomware, data protection and security - organizations can mitigate unauthorized user access and threats to data from ransomware attacks. Customers can protect a multitude of workloads, enterprise apps, virtualized workloads and modern containerized applications against security breaches, quickly detect attacks and rapidly recover data before experiencing any impact to operations.
Accelerating Enterprise Cloud Transformation –
NetApp is empowering customers to “modernize to the cloud” using a supplemental datastore for data-intensive, storage demanding workloads running in a single or across multicloud environments. NetApp is the only cloud storage service provider today to be certified and become supported for use as an external supplemental datastore for VMware Cloud environments running in the largest public clouds.
“Organizations across all industries rely on the combination of VMware and NetApp as the platform of choice for delivering business-critical workloads,” said Narayan Bharadwaj, vice president of Cloud Solutions at VMware. “NetApp is now able to deliver the same levels of enterprise-class data management that our mutual customers have enjoyed for decades on-premises to workloads running in any of the major public clouds.”
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
1 IDC's 2021 Ransomware Study: Where You Are Matters! (IDC #US US48093721) July 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
